Joint Pain Injections Market Size, Share & COVID-19 Impact Analysis, By Product (Corticosteroid Injections, Hyaluronic Acid Injections, Platelet Rich Plasma Injections, and Others), By Joint Type (Knee, Hip, Hand & Wrist, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2023-2030

The joint pain injections market was USD 4.79 billion in 2022 and is projected to grow from USD 5.16 billion in 2023 to USD 9.20 billion by 2030, exhibiting a CAGR of 8.6%. The growing number of treatments is attributed to the favorable reimbursement policies in developed countries.

The increasing prevalence of osteoarthritis, rheumatoid arthritis, and musculoskeletal disorders in the general population is responsible for the increasing number of patients suffering from joint pain and related complications. The rising awareness among the patient population regarding the condition and available treatment options are some of the major factors responsible for the rising demand for intra-articular injections for the treatment of joint pain in developed and emerging countries. Additionally, the growing awareness of the benefits of intra-articular injections in treating joint pain is responsible for the increasing demand for joint pain injections.

• According to 2020 data reported by WHO, approximately 1.71 billion people worldwide were suffering from musculoskeletal disorders in 2020. Also, according to estimates of the Centers for Disease Control and Prevention (CDC), in July 2020, osteoarthritis affected around 32.5 million U.S. adults.

Therefore, these factors along with robust efforts of the key market players to develop and introduce novel therapies for the treatment of osteoarthritis are anticipated to propel the demand and adoption of joint pain injections.

COVID-19 IMPACT

Deferral of Elective Procedures During COVID-19 Hampered the Market Growth 

The emergence of COVID-19 significantly hampered the demand for joint pain injections worldwide. The key players operating in the market reported a decline in their revenues during the period due to significant decrease in product sales.

• For instance, in 2020, Anika Therapeutics, Inc. generated a revenue of USD 83.0 million from its OA Pain Management witnessing a decline of around 19.8% as compared to the previous year.

The significant decline in the revenues for the pain injections industry was attributed to the reduced number of patient visits for treatment, declined number of elective procedures, and reallocation of healthcare resources for COVID-19 management.

• For instance, according to the research paper published in the Journal of Bone and Joint Surgery, the daily activities of orthopedic surgeons were hampered by 72.6% of the institutions during the first half of 2020. It also stated that around 50% of orthopedic practitioners were shifted from routine orthopedic work to COVID-19 patient management.

Moreover, the increased adoption of alternative treatment options, such as oral drugs, and others, during the pandemic is another factor that contributed to the decline of the market.

There was a disruption in business activities, such as manufacturing and logistics, due lockdown restrictions in major markets for pain injections. Therefore, a significant decline in growth was reported by major players in 2020. For instance, Bioventus Inc. recorded a 6% decline in revenues from OA joint pain treatment and joint preservation business segment in 2020 compared to 2019. The decline in revenues from joint pain injections was attributed to a decrease in the number of procedures performed in 2020.

However, with the ease of lockdown restrictions in 2021, the diagnosis rate of the condition among the population increased, and procedures and treatment services by healthcare providers globally were resumed. The market players witnessed growth in revenue as compared to 2020. For instance, Bioventus witnessed a growth of around 29.5% in its pain treatment segment in 2021 as compared to the previous financial year.

Thus, with the rising prevalence of osteoarthritis and other musculoskeletal conditions among the population globally and the rising number of product approvals and launches, the global market is expected to grow in the near future.

LATEST TRENDS

Request a Free sample to learn more about this report.

Rising Preference for Minimally Invasive Joint Pain Procedures among Healthcare Providers

The growing prevalence of osteoarthritis and other musculoskeletal disorders among the population especially in the geriatric population is leading to rising demand for joint pain injections. The rising geriatric population is another factor fueling the increasing demand for joint pain injections globally.

• According to 2021 data published by the U.S. Census Bureau, there were more than 76 million adults aged 65 years and above which accounted for around 17.1% of the U.S. population.

The increasing benefits of these injections such as their quick and painless process, minimally-invasive nature, rapid adsorption of the drug, longer relief period for patients, and others are resulting in increasing adoption of these injections among the healthcare provider.

Also, major players operating in the market are involved in the development of innovative treatment solutions such as platelet-rich plasma injections and plasma matrix therapy. Additionally, ongoing research activities highlight benefits associated with novel treatments, which support the adoption of innovative products.

• According to an article published by the U.S. National Library of Medicine, in July 2022, phase 3 clinical trials are carried on by Emory University on the effectiveness of injection with the composition constituting Mesenchymal Stem Cell (MSC) preparations from autologous Bone Marrow Concentrate (BMAC) and human mesenchymal stem cells manufactured from Umbilical Cord Tissue (UCT) for the treatment of knee osteoarthritis.

Additionally, the drugs currently available in the market such as hydrocortisone injections are generally administered in three or five injections. This factor is responsible for higher treatment costs and lack of adherence to the treatment. Therefore, key players operating in the market introduce single injection therapy. Single injection therapy is a more effective and saving option for treating joint pain. Also, according to RxList Inc., Monovisc, which is a hyaluronic acid visco-supplement single injection used for the therapy of joint pain associated with osteoarthritis, is equivalent to three injection therapy of Orthovisc by Anika Therapeutics, Inc.

Therefore, the introduction of innovative products in the market is responsible for increasing the shift of preference toward injections for joint pain management.

DRIVING FACTORS

Growing Prevalence of Osteoarthritis and Obesity in General Population to Surge Product Demand 

The rapid rise in the prevalence of osteoarthritis and other musculoskeletal disorders globally is the result of several factors, including the continuous rise in the geriatric population, and the shift toward the adoption of a sedentary lifestyle, in both developed and emerging countries worldwide.

• According to the United Nations, the global population aged 65 years and over is projected to increase from 727.0 million in 2020 to 1.5 billion in 2050. Also, according to the World Health Organization (WHO), it is estimated that around 10.0% to 15.0% of all adults aged over 60 years suffer from some degree of osteoarthritis (OA).


• Similarly, according to World Obesity Atlas 2022, 1 billion people globally, including 1 in 5 women and 1 in 7 men, will be living with obesity by 2030.

Thus, the presence of a large patient pool suffering from osteoarthritis and the growing awareness for early diagnosis & treatment are responsible for increasing demand for pain treatment products, including joint pain injections.

Increasing per capita expenditure on healthcare in developed countries and new product launches by market players bolster the demand for intra-articular injections in the global market. 

Rising R&D Activities Among Major Players & Pipeline Candidates to Fuel the Product Demand 

The rising prevalence of arthritis and other musculoskeletal disorders and increasing diagnosis rate among the general population are expected to fuel the demand for joint pain injections in the market.

The increasing R&D activities among the key players operating in the market to strengthen their product portfolio and develop novel products to cater to the rising demand among the patient population in the market is anticipated to augment the adoption of these products in the market.

The growing number of pipeline candidates by major players in the market is another crucial factor expected to propel the market growth.

• In April 2021, Ampio Pharmaceuticals Inc. received a positive response from the U.S. FDA on its plans for its phase 3 trial of Ampion, an intra-articular injection for the treatment of signs & symptoms of severe knee OA.

All the factors mentioned above along with rising partnerships and collaborations among major players and startups to develop and introduce novel products and therapies for various musculoskeletal disorders are projected to drive market growth.

RESTRAINING FACTORS

High Cost of Injections and Lack of Reimbursement Policies to Limit Adoption in Emerging Countries

The rising prevalence of musculoskeletal disease and the surge in demand for effective treatment are propelling the demand for these products. However, the high costs of these injections and stringent regulations for product approvals are some of the major factors estimated to limit the joint pain injections market growth.

• For instance, in March 2021, the U.S. FDA rejected Pfizer Inc. Eli Lilly and Company’s tanezumab for osteoarthritis pain due to some risk-benefit doubts. The FDA’s Arthritis Advisory Committee (AAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM) ruled that while clinical data suggested tanezumab can benefit patients with OA pain, the associated risk for joint destruction, or rapidly progressing osteoarthritis and other safety outcomes were more prominent, even with the proposed modification efforts.

Also, rising awareness about cost-effective alternatives for pain management among the patient population is another factor anticipated to hinder the demand for these injections in the market.

• According to a 2022 article published by the National Center of Biotechnology Information (NCBI), a course of physical therapy was more cost-effective as compared with a course of glucocorticoid injections for patients with knee osteoarthritis.

Limited reimbursement policies for these products in developing countries are anticipated to limit the adoption of these injections among the patient population. Moreover, lack of awareness about these products in developing countries is accountable for the lower adoption of intra-articular injections in the treatment of joint pain.

SEGMENTATION

By Product Analysis

To know how our report can help streamline your business, Speak to Analyst

Clinically Proven Benefits Increases Preference toward HA-based Injections Globally

Based on product, the market is segmented into corticosteroid injections, hyaluronic acid (HA) injections, platelet rich plasma injections, and others.

The HA injections segment accounted for the largest global joint pain injections market share in 2022. The growing number of patients with osteoarthritis pain and the rising awareness about clinical benefits offered by HA injections are responsible for the growing adoption of these products among osteoarthritis patients with moderate to severe pain.

Additionally, the rising number of product approvals for HA injections, also referred to as viscosupplements/gel injections are anticipated to further augment the segment's growth in future.

• For instance, in March 2021, SEIKAGAKU CORPORATION’s JOYCLU received manufacturing and marketing approval from the Ministry of Health, Labor and Welfare (MHLW) of Japan for the treatment of osteoarthritis.

On the other hand, the corticosteroid injections segment held the second largest market share. These are usually the first line of treatment for osteoarthritis preferred by clinicians. The increasing prevalence and diagnosis rate of these conditions among the general population globally is one of the major factors contributing to the growth of the segment.

The platelet rich plasma injections segment is anticipated to register a higher CAGR than other segments due to the increasing number of clinical trials to establish the efficiency of platelet-rich plasma therapy for pain management among osteoarthritis patients and their projected approvals.

• In July 2020, Ondokuz Mayıs University of Turkey conducted a clinical trial on Platelet Rich Plasma (PRP) injection to study its effect in the treatment of patients suffering from pain associated with knee osteoarthritis.

By Joint Type Analysis

Higher Prevalence of Joint Pain in Knee is Responsible for Higher Share of the Segment 

On the basis of joint type, the market is segmented into knee, hip, hand & wrist, and others.

The knee segment accounted for the largest market share in 2022 and is expected to grow at a significant CAGR during the forecast period. The increasing demand for intra-articular injections for the management of knee pain is attributed to the rising cases of knee osteoarthritis.

• 
  
  
  
  • According to a study published by the National Center for Biotechnology Information in 2020, it was observed that the global prevalence of knee osteoarthritis (OA) was 16.0% among people aged 15 years and older and was 22.9% among individuals aged 40 years and older.
  
  
  
  

Moreover, the knee segment is expected to dominate the global market share owing to factors such as strong product portfolio offered by key players for the treatment of pain associated with knee osteoarthritis and the growing number of product approvals for knee osteoarthritis.

• In December 2021, Xalud Therapeutics announced that the U.S. Food and Drug Administration (FDA) granted fast track designation to the company’s lead candidate, XT-150, for the treatment of pain associated with knee osteoarthritis.

The hand & wrist segment accounted for the second-largest share of the market in 2022. The growth of this segment is attributed to the increasing incidence of hip osteoarthritis among the global population coupled with the growing number of clinical trials for this indication.

Hip segment is expected to grow at a considerable CAGR during the forecast period. The growth of the segment is attributed to various factors such as increasing prevalence of the condition among the general population, increasing diagnosis rate, and rising number of patients taking treatment for the condition.

• According to 2019 data published by the Global Burden of Disease Study (GBD), there were around 3.2 million Australians with osteoarthritis in 2019, and hip osteoarthritis reported a significant growth in the prevalence rate as compared to other joint types.

The others segment is expected to grow owing to the rising prevalence of other joint types such as spine and foot & ankle, among others. The rising adoption of the treatment among the population globally is another major factor driving the growth of the segment.

By Distribution Channel Analysis

Retail Pharmacies Dominated the Market Owing to the Rising Number of Pharmacies 

The market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies based on distribution channel.

The retail pharmacies segment held the largest share in the global market in 2022. The dominance is due to the increasing number of retail pharmacies supplying joint pain injections globally.

On the other hand, the online pharmacies segment is anticipated to record a significant CAGR during the forecast period. The rising regulatory policies for online sales of prescription drugs in developed countries and the entry of leading e-pharmacy players in Germany, the U.K., and other countries are leading to a shift in patient preference toward online pharmacies.

Along with this, the lower selling prices of the injections by the online pharmacies is another major factor responsible for the growth of the segment.

• For instance, Synvisc injection, used to treat joint pain in osteoarthritis patients, is sold on the Canada Pharmacy website for USD 100-150 per 2ml syringe, whereas the same product costs around USD 300-350 per 2ml syringe in offline stores.

The hospital pharmacies segment is anticipated to grow owing to factors such as the growing hospitalization rate of patients suffering from orthopedic conditions, rising patient visits to hospitals for the diagnosis of the condition, and others.

REGIONAL INSIGHTS

To get more information on the regional analysis of this market, Request a Free sample

North America to Hold Largest Market Share due to Well-established Reimbursement Policies

North America dominated the global market in 2022, with a valuation of USD 2.15 billion. The growing patient population suffering from joint pain, well-established reimbursement policies for intra-articular injections, and the increasing focus of market players on catering to the demand in countries such as the U.S. and Canada are the major factors responsible for driving the growth of the North America market.

• According to a 2021 data published by the Osteoarthritis Action Alliance, osteoarthritis is the most common form of arthritis, affecting 32.5 million adults in the U.S.

Europe accounted for the second-largest market share since a large patient pool suffers from pain associated with musculoskeletal disorders such as arthritis. Further, the presence of skilled professionals and the introduction of novel intra-articular pain injections in Europe is expected to foster growth.

The rising focus of the players in the market to develop and launch novel therapies for knee osteoarthritis in the region is another major factor anticipated to spur the demand and adoption of the injections in the region.

• For instance, in February 2022, Synartro AB, a Swedish life science company developing novel therapies, was granted the European patent for its drug delivery platform, which strengthens the company’s position for its lead candidate, SYN321, which is developed for the treatment of knee osteoarthritis.

On the other hand, the Asia Pacific joint pain injections market growth is expected to be highest during the forecast period. The growing prevalence of osteoarthritis and the introduction of viscosupplement products by players in the region are driving the market growth in Asian countries. Moreover, the rising awareness about innovative treatments for joint pain in the region also provides favorable conditions for adoption of these treatments among the patient population.

• According to the 2019 Global Burden of Disease Study, the prevalence of osteoarthritis was highest in Asian countries such as China, Japan, India, and others. The prevalence of osteoarthritis in China was around 132.8 million cases, and in India, the prevalence was around 62.4 million in 2019.

Latin America and the Middle East & Africa regions held a lower share in the global market. However, the increasing cases of arthritis and the rising adoption of technologically advanced solutions for pain management in these regions are expected to drive the market growth in the near future.

• According to a 2020 study published by the World Health Organization (WHO)/International League Associations for Rheumatology Community Oriented Program for the Control of Rheumatic Diseases (COPCORD), the prevalence of osteoarthritis is increasing in Latin American countries, with prevalence rates of 10.5% in Mexico, 4.1% in Brazil, 14.4% in Peru, and 20.4% in Cuba. Also, knee osteoarthritis accounted for around 45.0% of the total osteoarthritis cases in Latin American countries.


• Similarly, according to a 2020 article published by the National Library of Medicine, the prevalence of knee osteoarthritis in Africa is 21.0% among the population.

The rising focus of the market players to increase the accessibility and penetration of their products in these emerging countries is anticipated to drive the adoption of pain injections in these regions.

KEY INDUSTRY PLAYERS

Strong Portfolio of Sanofi, Zimmer Biomet, Bioventus Inc., and Anika Therapeutics, Inc. to Boost Market Position 

The global market is fragmented, with several players operating with a wide product portfolio globally.

The key players, such as Sanofi, Bioventus Inc., Anika Therapeutics, Inc., and others, dominated the market in 2022. The dominance of these players is attributed to their strong distribution network, strategic collaborations, and robust product portfolio of intra-articular injections. The key companies operating in the market are developing innovative products to gain a competitive advantage over other market players.

The rising focus of these companies on increasing the accessibility and adoption of their viscosupplementation products is anticipated to fuel their market share.

• In May 2022, Bioventus agreed to a nationwide contract with Cigna commercial plans in which the Cigna commercial plan members will have access to both DUROLANE and GELSYN-3 to treat knee osteoarthritis pain.

Similarly, the increasing number of strategic mergers and acquisitions among the market players is another factor propelling the market share of these players. These strategic partnerships and collaborations are expected to increase the accessibility and availability of the products globally, which is leading to a growing adoption of these products among the patient population.

Other players, such as Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, and others, dominated the global market with their corticosteroid injection product portfolio.

LIST OF KEY COMAPNIES PROFILED:

• Sanofi (France)


• SEIKAGAKU CORPORATION (Japan)


• Bioventus (U.S.)


• Anika Therapeutics, Inc. (U.S.)


• Pacira BioSciences, Inc. (U.S.)


• Dr. Reddy’s Laboratories Ltd. (India)


• Zimmer Biomet (U.S.)


• Teva Pharmaceutical Industries Ltd. (Israel)


• Ferring B.V. (Switzerland)

KEY INDUSTRY DEVELOPMENTS:

• April 2022 - Dr. Reddy’s Laboratories Ltd. launched Methylprednisolone Sodium Succinate for Injection, USP, the generic equivalent of SOLU-MEDROL in the U.S. for the treatment of arthritis, blood disorders, and several allergic conditions.


• March 2022 – Sanofi collaborated with IGM Biosciences Inc. to develop, manufacture, and introduce potential therapeutics in the fields of immunology and inflammation.


• November 2021 - Pacira Biosciences Inc. acquired Flexion Therapeutics Inc. with an aim to strengthen its product portfolio in novel and non-opioid treatments for various musculoskeletal disorders.


• September 2021 – Bioventus announced that the American Academy of Orthopedic Surgeons (AAOS) recently released updated Clinical Practice Guidelines (CPG) indicating that high molecular weight cross-linked hyaluronic treatments, including DUROLANE, showed statistically significant improvement in certain knee osteoarthritis (OA) patients.


• May 2021 - SEIKAGAKU CORPORATION and ONO PHARMACEUTICAL CO., LTD. launched JOYCLU, an intra-articular injection for joint function management, in Japan.

REPORT COVERAGE

An Infographic Representation of Joint Pain Injections Market

View Full Infographic

To get information on various segments, share your queries with us

The research report provides an overall scenario of the market. It focuses on key aspects such as leading companies, product, joint type, and distribution channels. Besides this, it offers insights into the trends in the global market, highlights key industry developments, and COVID-19 impact on the market. In addition to the factors mentioned above, the report encompasses several factors that have contributed to the market growth in recent years.

Report Scope & Segmentation